In addition, the funds will support delafloxacin‘‘s two ongoing Phase 3 trials for the treatment of acute bacterialskin and skin structure infections (ABSSSI) and the selection of leadcandidates from Melinta‘‘s RX-04 research program. The RX-04 program is focusedon the creation of novel molecular structures and selection of uniquecandidates that target novel binding sites on the bacterial ribosome. Melintaplans to select lead candidates and advance IND-enabling studies in 2014 forthe treatment of serious and life-threatening infections caused by multi-drugresistant Gram-negative microbes.
此外，基金支持德拉沙星两项在进行的用于治疗急性细菌性皮肤和皮肤组织感染(ABSSSI)的III期临床试验，以及筛选Melinta公司RX-04研究项目中最重要的在研药物。RX-04项目着重于新分子结构产物的研发和独特在研药物的筛选，目标是细菌核糖体新的结合位点。Melinta公司计划选出先进的在研药物并在2014年推进治疗多重耐药性的革兰氏阴性菌引起重度和威胁生命的感染的IND-授权试验。